POPULARITY
7 episodes with dyskinesia
12 episodes with dyskinesia
5 episodes with dyskinesia
3 episodes with dyskinesia
12 episodes with dyskinesia
2 episodes with dyskinesia
3 episodes with dyskinesia
2 episodes with dyskinesia
2 episodes with dyskinesia
What causes dyskinesia in Parkinson's Disease, and why does it often appear as a side effect of treatment? In this video, we explore the science behind Parkinson's dyskinesia—a condition characterized by involuntary, erratic movements that can significantly impact quality of life. We'll break down: -How long-term use of levodopa (a common Parkinson's medication) can lead to dyskinesia. -The role of dopamine fluctuations and brain receptor changes in causing these movements. -Insights into other contributing factors and strategies for managing dyskinesia effectively. Whether you're living with Parkinson's or supporting someone who is, this video offers a deeper understanding of this challenging symptom and what can be done to address it. Join me in a FREE webinar 5 Top Parkinson's Myths and How to Debunk Them on Jan 8th, Jan 15th, and Jan 17th. Here is the link to register: https://pdeducation.podia.com/webinars Help to support this channel and out efforts to educate the world about Parkinson's Disease and get access to personalized content: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join https://www.patreon.com/pdeducation Please be sure to give support to our channel sponsors: Comfort Linen: https://comfortlinen.com/PARKINSONSDISEASEEDUCATION(15% off entire order when applying the code PARKINSONSDISEASEEDUCATION at checkout) Kizik Shoes: https://kizik.sjv.io/pdeducation Cure Hydration: https://lvnta.com/lv_XG06Rho8SSlXEq3qlV If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013 Medical Disclaimer All information, content, and material of this video is for informational purposes only and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Affiliate disclaimer: Keep in mind that links used for recommended products may earn me a commission when you make purchases. However, this does not impact what products I recommend. If I recommend a specific product it is because it has been vetted by myself or based on personal use #parkinson #parkinsonsawareness #parkinsonsdisease #parkinsons #dyskinesia #dopamine
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/streamlined-strategies-for-managing-tardive-dyskinesia-9842SummaryTardive dyskinesia (TD) is a debilitating movement disorder that manifests as involuntary, repetitive movements, often of the face, tongue, and extremities. These symptoms frequently result from prolonged use of antipsychotic medications, particularly in patients being treated for schizophrenia, bipolar disorder, or major depressive disorder. Accurate and routine assessment of TD is critical to prevent symptom progression and improve patient outcomes. The Abnormal Involuntary Movement Scale (AIMS) is a widely accepted, gold-standard tool used to detect and measure the severity of involuntary movements. AIMS enables clinicians to detect involuntary movements early and track the disorder's progression, facilitating timely intervention and individualized treatment plans.In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic delve into the complexities of diagnosing and managing tardive dyskinesia (TD), emphasizing evidence-based strategies to improve patient outcomes. They discuss the importance of using the Abnormal Involuntary Movement Scale (AIMS), a standardized and validated tool, for regular TD assessment. AIMS enables clinicians to detect involuntary movements early and track the disorder's progression, facilitating timely intervention and individualized treatment plans.Learning ObjectiveAt the conclusion of this activity, participants should be better able to:Explore strategies to simplify management and optimally improve outcomes for patients with TDThis activity is accredited for CME/CE CreditThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from Neurocrine Biosciences.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
In today's episode, we dive deep into two groundbreaking studies led by Daniela and Clément. We explore their 2022 Nature Communications paper on using cerebellar stimulation to alleviate levodopa-induced dyskinesias in Parkinson's disease and discuss their 2023 paper uncovering the cerebellum's role in regulating fear extinction through its connections with the thalamo-prefrontal cortex pathway. Along the way, we discuss how these discoveries may open up exciting new possibilities for treating both motor and emotional disorders. Tune in for an insightful conversation packed with cutting-edge science and exciting future perspectives!
In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: October 23, 2024* Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.
Host: Ashley Baker, MSN, PMHNP Guest: Richard Jackson, MD The Impact-TD scale enables us to evaluate the effects of tardive dyskinesia across four key domains: psychological/psychiatric, social, physical, and vocational/educational/recreational. By using this assessment tool, we can not only gain a deeper understanding of how our patients are impacted by tardive dyskinesia, but it can also foster better communication and treatment outcomes. To learn more, psychiatric nurse practitioner Ashley Baker speaks with Dr. Richard Jackson, Associate Clinical Professor at the Oakland Beaumont University School of Medicine and an Assistant Clinical Professor at the University of Michigan School of Medicine.
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrew J. Cutler, MD Guest: Michelle Scargle, MD Tardive dyskinesia is quite common as up to 20 percent of patients may develop this hyperkinetic movement disorder. But despite its prevalence, there are many barriers that can keep us from screening patients for tardive dyskinesia. To learn more about these barriers and how we can overcome them to optimize our screening approach, Dr. Charles Turck speaks with Drs. Andrew Cutler and Michelle Scargle. Dr. Cutler is a Clinical Associate Professor in the Department of Psychiatry and Behavioral Sciences at the SUNY Upstate Medical University in Syracuse, New York, and Dr. Scargle is the Chief Psychiatrist at Concord Health in Clearwater, Florida.
Don't miss the Signs: Early Recognition and Management of Tardive Dyskinesia In this episode, Amber Hoberg and Dr. Jennifer Sampang bring us an engaging discussion on the complexities of tardive dyskinesia, the significance of early detection and treatment, and the considerable burden it has on patients. As they unwind the mysteries of TD, we get a better understanding of the importance of being vigilant and proactive in detecting it and keeping our patients informed and involved in their treatment plans. Together, through early recognition, informed discussions, and shared decision-making, we can mitigate the impact of TD and improve the lives of those affected. Additionally, a Tardive Dyskinesia Point-of-Care tool will be available on AANP's Tools and Resources page. To earn 1.0 contact hours of continuing education (CE) credit, you will need the participation code provided at the end of the podcast. To claim your CE credit, log in and register for the activity within the AANP CE Center log in and register for the activity within the AANP CE Center, then enter the participation code and complete the posttest and evaluation. CE credit is available for this podcast through August 2025. This educational activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.
In this episode, Dr. Amita Patel, MD, CMD, MHA, CPE, a Geriatric Psychiatrist at Joint Township Memorial Hospital in Dayton, Ohio, shares her insights into what tardive dyskinesia is, its risk factors, and its impact on older adults and caregivers, highlighting the importance of early recognition and management of this frequently underdiagnosed movement disorder in the long-term care setting.Dr. Amita Patel, MD, CMD, MHA, CPE, is a Geriatric Psychiatrist at Joint Township Memorial Hospital in Dayton, Ohio.This podcast is an educational program sponsored and co-developed by Neurocrine Biosciences.Neurocrine Biosciences is a pioneering company with over 30 years of experience dedicated to discovering and developing life-changing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Learn more: https://www.neurocrine.com/Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com
On this MADM, Rakesh Jain, MD, MPH, Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine is joining me to discuss tardive dyskinesia, its impact on peoples' lives and the importance of this treatment formulation. Listen and share. Sponsor: Bankston Motor Homes BankstonMotorHomes.com
Currently, more than 14 million Americans have a serious mental illness, such as bipolar disorder, major depressive disorder and schizophrenia, conditions that can be treated with antipsychotic medicines. Use of these medicines has increased 22%, increasing the risk for developing a debilitating chronic movement condition called tardive dyskinesia. Tardive dyskinesia can cause debilitating uncontrollable and repetitive movements that can make eating, drinking and walking difficult. While tardive dyskinesia can be treated, integrating new medicines into any existing treatment plan can be challenging. Sometimes regimens can become complex causing patients to feel overwhelmed and give up on treatment or go without treatment entirely. The U.S. Food and Drug Administration has approved a new treatment formulation – one pill, taken once-daily – that could help the millions of Americans living with a serious mental illness whose antipsychotic medications may cause this condition. This new formulation of an established treatment can be integrated into existing mental health treatment plans. On tonight's show, Rakesh Jain, MD, MPH, Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine is joining me to discuss tardive dyskinesia, its impact on peoples' lives and the importance of this treatment formulation and Sherland Peterson is sharing her experience with TD, and how it has impacted her quality of life.
In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024* Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.0 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Laxman B. Bahroo, DO, MS, FAAN Professor and Residency Program Director, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC Consultant/Advisor: AbbVie, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Revance, Supernus Speakers Bureau: AbbVie, Acadia, Acorda, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Supernus, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, Brielle Calleo, and Andrea Zimmerman, EdD. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.
In this CME episode, Dr. Andrew Cutler interviews Desiree Matthews, PMHNP-BC on the importance of engaging patients across all facets of tardive dyskinesia management beginning with screening to symptoms monitoring to treatment. The role of patient experience and preferences in shared decision-making regarding treatment for tardive dyskinesia is discussed at length. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Recognize the significance of comprehensive measures that assess both healthcare practitioner-perceived severity of tardive dyskinesia symptoms and the patient-reported impact of tardive dyskinesia on daily life Engage in informed discussions with patients about the rationale behind incorporating additional medications to manage side effects arising from primary antipsychotic medication Consider all facets of patient health, including physical, mental, and social well-being, when formulating strategies for managing tardive dyskinesia symptoms Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour. Released: June 05, 2024* Expiration: June 04, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-01-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.00 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.5 continuing education hour(s) of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour(s) (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). Approval is valid until June 04, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Desiree M. Matthews, MSN, PMHNP-BC Founder and Clinical Director, Different MHP, PC, Charlotte, NC Consultant/Advisor: Alkermes, Biogen, Boehringer Ingelheim, Karuna, Indivior, Janssen Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Takeda, Teva Speakers Bureau: AbbVie, Axsome, Neurocrine Biosciences, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, and Andrea Zimmerman. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.
Welcome to another enlightening episode of IDD Health Matters, where we delve into crucial health topics for individuals with intellectual and developmental disabilities. In today's episode, sponsored by Neurocrine Biosciences, we shed light on the often overlooked issue of Tardive Dyskinesia (TD) in people with IDD. Join Dr. Craig Escude as he welcomes Dr. Sharon Cahoon-Metzger, an expert in the field, to explore the burden and impact of TD. Dr. Cahoon-Metzger expertly guides us through the complexities of TD, describing it as a condition characterized by abnormal involuntary movements resulting from prolonged use of certain medications. She emphasizes the importance of early recognition and diagnosis, highlighting the significant risk factors associated with TD, including age, medication potency, and anti-cholinergic treatment. Throughout the episode, Dr. Cahoon-Metzger paints a vivid picture of the diverse manifestations of TD, from orobuccal movements to limb dyskinesia, underscoring the challenges in diagnosis and management. She shares compelling case studies that illustrate the profound impact of TD on individuals' daily lives, from social isolation to diminished independence. Dr. Escude and Dr. Cahoon-Metzger stress the crucial role of interdisciplinary collaboration in identifying and addressing TD symptoms. They emphasize the need for heightened awareness among caregivers and healthcare professionals, advocating for regular monitoring and early intervention. Listeners are encouraged to leverage available resources, including educational materials provided by Neurocrine Biosciences, to enhance their understanding of TD and improve patient outcomes. As the episode draws to a close, Dr. Escude and Dr. Cahoon-Metzger urge listeners to join the collective effort in mitigating the long-term impacts of TD, ultimately striving to enhance the quality of life for individuals with IDD. Tune in to gain invaluable insights into TD and empower yourself to make a difference in the lives of those we support.
Welcome to another enlightening episode of IDD Health Matters, where we delve into crucial health topics for individuals with intellectual and developmental disabilities. In today's episode, sponsored by Neurocrine Biosciences, we shed light on the often overlooked issue of Tardive Dyskinesia (TD) in people with IDD. Join Dr. Craig Escude as he welcomes Dr. Sharon Cahoon-Metzger, an expert in the field, to explore the burden and impact of TD. Dr. Cahoon-Metzger expertly guides us through the complexities of TD, describing it as a condition characterized by abnormal involuntary movements resulting from prolonged use of certain medications. She emphasizes the importance of early recognition and diagnosis, highlighting the significant risk factors associated with TD, including age, medication potency, and anti-cholinergic treatment. Throughout the episode, Dr. Cahoon-Metzger paints a vivid picture of the diverse manifestations of TD, from orobuccal movements to limb dyskinesia, underscoring the challenges in diagnosis and management. She shares compelling case studies that illustrate the profound impact of TD on individuals' daily lives, from social isolation to diminished independence. Dr. Escude and Dr. Cahoon-Metzger stress the crucial role of interdisciplinary collaboration in identifying and addressing TD symptoms. They emphasize the need for heightened awareness among caregivers and healthcare professionals, advocating for regular monitoring and early intervention. Listeners are encouraged to leverage available resources, including educational materials provided by Neurocrine Biosciences, to enhance their understanding of TD and improve patient outcomes. As the episode draws to a close, Dr. Escude and Dr. Cahoon-Metzger urge listeners to join the collective effort in mitigating the long-term impacts of TD, ultimately striving to enhance the quality of life for individuals with IDD. Tune in to gain invaluable insights into TD and empower yourself to make a difference in the lives of those we support.
The Experts Speak - An Educational Service of the Florida Psychiatric Society
Stuart Isaacson, M.D., neurologist, explains TD, the role of dopamine in psychiatric and then this treatment induced consequential movement disorder, proper diagnosis, how both psychiatric and neurologic treatments are very helpful, but he also weighs the risk-benefits of now the increasing use of antipsychotics for mood disorders. He further talks of the VMAT2 systems empowering the two new medications. Important material. May 2024.
On Rare Disease Day, we're joined by John Matthews, Chief Medical Officer at ReCode Therapeutics. John and Patrick discuss how ReCode is using lipid nanoparticle technologies to revolutionise delivery of novel mRNA and gene correction therapies to Primary Ciliary Dyskinesia (PCD) and cystic fibrosis patients. Listen in to find out how ReCode and Sano are collaborating to offer eligible patients free genetic testing to better understand the mechanisms behind DNAI1-related PCD, and much more. See here: https://thinkpcd.com/
Live Nursing Review with Regina MSN, RN! Every Monday & Wednesday we are live. LIKE, FOLLOW, & SUB @ReMarNurse for more. 7 Day of NCLEX: https://ReMarNurse.com/7days Quick Facts for NCLEX Next Gen Study Guide here - https://bit.ly/QF-NGN Study with Professor Regina MSN, RN every Monday as you prepare for NCLEX Next Gen. ► Create Free V2 Account - http://www.ReMarNurse.com ► Get Quick Facts Next Gen - https://bit.ly/QF-NGN ► Subscribe Now - http://bit.ly/ReMar-Subscription ► GET THE PODCAST: https://remarnurse.podbean.com/ ► WATCH LESSONS: http://bit.ly/ReMarNCLEXLectures/ ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/ ReMar Review features weekly NCLEX review questions and lectures from Regina M. Callion MSN, RN. ReMar is the #1 content-based NCLEX review and has helped thousands of repeat testers pass NCLEX with a 99.2% student success rate! ReMar focuses on 100% core nursing content and as a result, has the best review to help nursing students to pass boards - fast!
In this podcast, we explore scapular dyskinesis, the abnormal movement of the shoulder blade. We discuss related terms like scapular misalignment and sick scapula, questioning the practicality of assessing it through visual observation. We highlight that identifying it as normal or abnormal may not guide treatment decisions or pinpoint the cause of shoulder pain. We also address its prevalence in athletes and non-athletes and suggest using various tests to assess scapular dyskinesis. Intriguingly, we'll reveal a surprising connection between scapular dyskinesis and an unexpected aspect of training, which might change the way you think about shoulder issues. So, join us for the full episode to uncover this fascinating insight. Guest Filip Struyf is a sportsphysiotherapist and professor at the Department of Rehabilitation Sciences and Physiotherapy at the University of Antwerp, Belgium. According to Expertscape, he is the #1 shoulder researcher world-wide. He teaches shoulder courses nationally and internationally and has created an online course together with us called “Rotator Cuff Related Shoulder Pain: Separating Facts from Fiction”. Content 00:00 Intro 01:15 The "correct" definition 04:05 What is "normal" 12:05 Prevalence 14:21 Is it a functional adaptation? 16:46 Scapula Dyskinesia as a risk factor? 26:09 How do we assess it? 28:51 How reliable or valid is assessment? 32:39 Can we improve scapula movement? 39:09 What's up with focussing on the lower trapezius? 42:26 What about Rhomboid Pain? 46:21 Is there a place for scapula mobilization techniques? 49:42 Filip's closing thoughts 52:15 Outro Bonus Material To view and download the bonus content such as transcripts of this episode become a Physiotutors Member. All episodes and bonus content can be found here Follow our Podcast on: Spotify | Apple Podcasts
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
Thank you for listening to this episode of "Health and Fitness" from the Nezpod Studios! Enjoy your night or the start of your day, spiced by our top-notch health and fitness/wellness updates coined from the best sources around the globe: made only for your utmost enjoyment and enlightenment… Click on subscribe to get more spicy episodes for free! See you again soon on the next episode of Health and Fitness Updates! Learn more about your ad choices. Visit megaphone.fm/adchoices
CME credits: 1.00 Valid until: 18-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/identification-and-management-of-tardive-dyskinesia/16088/ Tardive dyskinesia (TD) can be observed in patients receiving long-term treatment with dopamine receptor blocking agents. As the indications for these agents have expanded, TD is becoming more prevalent. In this activity, an expert reviews TD including risk factors, prevention, and treatment. =
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/whos-at-risk-for-tardive-dyskinesia-9044 Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD. SummaryTardive Dyskinesia (TD) exerts a profound negative impact across a patient's life, including physical and cognitive domains and psychosocial functioning. This affects quality of life (QoL), increases hospitalizations and is associated with speech and eating difficulties, decreased employment, social withdrawal, stigmatization, and amplified emotional distress. In this podcast, hear from a patient who suffered with TD for years before diagnose, and discuss how to identify and support patients with TD.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify the early manifestations of tardive dyskinesia (TD) in patients on antipsychotic therapyRecognize the burden associated with untreated TD and the consequences of delayed diagnosisThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/managing-tardive-dyskinesia-9045Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD.SummaryBesides identification of patients with Tardive Dyskinesia (TD), management options have not always provided much, if any, relief. Traditional approaches to managing TD were not only questionable, and some were potentially harmful, but the availability of newer medications has ushered in a new era in TD management. In this activity, discuss management principles and review two cases to put TD management into practice.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Individualize the management of TD using evidence-based strategies that target uncontrolled movementsThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
In this replay of audio from our Third Thursdays Webinar, Michael J. Fox Foundation Patient Council member Larry Gifford leads a discussion on common Parkinson's issues — dyskinesia and "off" time — and how to treat them. Like our podcasts? Please consider leaving a rating or review and sharing the series with your network. https://apple.co/3p02Jw0 Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything. Find out more at michaeljfox.com/podcast-ppmi.
Catch another installment in our series – this week I was joined by Dr. Deborah Bier, Ph.D. to discuss movement disorders. Living with Parkinson's can be a challenge, but it is not the end. Connect with the right Neurologist, develop a life plan, and live your best life possible. Stay active.
Tidal Volume is a podcast from ATS Assembly on Pediatrics focusing on core concepts of pediatric pulmonology. The goal is to bring in depth focus on these core concepts for residents, fellows, early career pulmonologists or even senior faculty looking for a refresher.In episode 8, Drs. Kubra Melike Bozkanat and Yadira Rivera-Sanchez from University of Texas Southwestern discuss pathophysiology, diagnosis and treatment of Primary Ciliary Dyskinesia. ReviewersRyan Thomas, MDMichigan State University College of Human MedicineChristina Barreda, MDUniversity of Wisconsin School of Medicine and Public HealthReferences Hannah, W., et al. "Frequency of CFTR Mutations in Individuals Evaluated for Primary Ciliary Dyskinesia." B25. CHRONIC SUPPURATIVE LUNG DISEASE IN CHILDREN. American Thoracic Society, 2018. A2843-A2843. Leigh, Margaret W., et al. "Clinical features and associated likelihood of primary ciliary dyskinesia in children and adolescents." Annals of the American Thoracic Society 13.8 (2016): 1305-1313. Shapiro, Adam J., et al. "Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review." Pediatric pulmonology 51.2 (2016): 115-132. Shoemark, Amelia, et al. "ERS and ATS diagnostic guidelines for primary ciliary dyskinesia: similarities and differences in approach to diagnosis." European Respiratory Journal 54.3 (2019). Shapiro, Adam J., et al. "The prevalence of clinical features associated with primary ciliary dyskinesia in a heterotaxy population: results of a web-based survey." Cardiology in the Young 25.4 (2015): 752-759. Collins, Samuel A., et al. "Nasal nitric oxide screening for primary ciliary dyskinesia: systematic review and meta-analysis." European Respiratory Journal 44.6 (2014): 1589-1599. Shapiro, Adam J., et al. "Nasal nitric oxide measurement in primary ciliary dyskinesia. A technical paper on standardized testing protocols." Annals of the American Thoracic Society17.2 (2020): e1-e12. Davis, Stephanie D., et al. "Primary ciliary dyskinesia: longitudinal study of lung disease by ultrastructure defect and genotype." American journal of respiratory and critical care medicine 199.2 (2019): 190-198. Horani, Amjad, and Thomas W. Ferkol. "Understanding primary ciliary dyskinesia and other ciliopathies." The Journal of pediatrics 230 (2021): 15-22. Zariwala, Maimoona A., Michael R. Knowles, and Margaret W. Leigh. "Primary ciliary dyskinesia." GeneReviews®[Internet](2019). Contact InformationTidalVolumeATSPeds@gmail.comTwitter@ATSPeds
There are four attributes of a vertebral subluxation that contribute to brain-body ‘mismatching'.
Are trauma, medication injury, and holistic health connected? Does Lyme disease infection relate to tardive dyskinesia from psychiatric drugs? Is there a spiritual purpose to debilitating illness? Monica Cassani is a psychiatric survivor and early leader in internet support with the Beyond Meds – Everything Matters website and community. Monica's struggle with chronic iatrogenic illness […] The post Lyme And Dyskinesia | Monica Cassani | Madness Radio first appeared on Madness Radio.
HAPPY NEW YEAR!! In the inaugural episode of 2023 we will be discussing Parkinson's Dyskinesia, root causes, and possible treatments. Information shared in today's episode is from Parkinson's Foundation. Please support this podcast and our endeavors by becoming a co-producer of the show! Sign up as a Patreon supporter here at https://www.patreon.com/pdwarriors Also, you can leave a one time tip in our virtual tip jar at: https://paypal.me/hylandptw Don't forget about our YouTube channel!!
In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.Presenters:Christoph U. Correll, MDProfessor of Psychiatry and Molecular MedicineThe Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellNew York, New YorkProfessor of Child and Adolescent PsychiatryCharité – Universitätsmedizin BerlinBerlin, GermanyJohn M. Kane, MDVice President for Behavioral Health ServicesNorthwell HealthChairman of PsychiatryZucker Hillside HospitalQueens, New YorkChairman of PsychiatryProfessor of Psychiatry and Molecular MedicineZucker School of Medicine at Hofstra/NorthwellHempstead, New YorkFor more programs in this series, visit:https://bit.ly/3AhRXau
Primary Ciliary Dyskinesia (PCD) is a rare genetic disease that results in severe sinus and pulmonary infections and is particularly difficult to treat; however, as George Solomon, MD, explains, researchers have recently made important steps in understanding and treating PCD. He explains the critical link they have established between genotype and phenotype of observed PCD cases, which will lead to genetic-based therapies in the future. Equally important, he says, are the strides made in treating symptoms PCD that can help patients right now: UAB is currently conducting clinical trials exploring treatments that help patients clear mucus from their lungs in order to limit damage throughout the body.
Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkCharles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaStuart Isaacson, MDDirectorParkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, FloridaClinical Associate Professor of NeurologyFIU Herbert Wertheim College of MedicineMiami, FloridaGreg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriJonathan M. Meyer MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis ProgramRajesh Pahwa, MDChief, Parkinson and Movement Disorder DivisionDirector, Parkinson Foundation Center of ExcellenceUniversity of Kansas Medical CenterKansas City, KansasFor more programs in this series, visit: https://bit.ly/3Bg0oTv
In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.Presenters:Robert O. Cotes, MDAssociate ProfessorDepartment of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlanta, GeorgiaJonathan M. Meyer, MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis Program
In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.Presenters:Diana O. Perkins, MD, MPHProfessor, PsychiatryUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaRajiv Tandon, MDEmeritus Professor of PsychiatryDepartment of PsychiatryWestern Michigan University Homer Stryker MD College of MedicineKalamazoo, MichiganThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.For more programs in this series, visit:https://bit.ly/3yOL8f7
In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.Presenters:Joseph P. McEvoy MDProfessorPsychiatry and Health BehaviorPsychiatristAugusta UniversityAugusta, GeorgiaLeslieThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.For more programs in this series, visit:https://bit.ly/3dUCVi6
In today's CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03 Learning Objectives: After completing this educational activity, you should be better able to: Recognize the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia Individualize treatment regimens for patients with tardive dyskinesia, utilizing FDA-approved medications Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva IntervieweeLeslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options) Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: July 27, 2022 CME/CE credit expires: July 27, 2025
In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriJonathan M. Meyer, MDVoluntary Clinical ProfessorDepartment of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis ProgramThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.For more programs in this series, visit: https://bit.ly/3AhRXau
Dyskinesia is a condition involving erratic, uncontrollable muscle movements such as twitches, jerks, twisting, or writhing of the face, arms, legs, or trunk. It can be a complication after long-term use of levodopa to treat Parkinson's disease. Dyskinesias can be mild, or they may be severe enough to interfere with normal functioning. Basic laboratory research has revealed some of the changes in the brain after long-term exposure to levodopa. In this episode, Kathy Steece-Collier, PhD, a professor in the Department of Translational Neuroscience in the Michigan State University College of Human Medicine in Grand Rapids, discusses her research into the biologic mechanisms of levodopa-induced dyskinesias and a possible future prevention and treatment for them. Funded by an International Research Grant from the Parkinson's Foundation, she delineated the role of calcium channels, which allow calcium to enter nerve cells in the brain, in the development of levodopa-induced dyskinesias. Based on those findings, she is now working on an approach that uses a single injection into a part of the brain that is affected in Parkinson's disease (the striatum) that may have the potential for long-term prevention or relief of dyskinesias. The idea is to introduce a short piece of RNA with a tight hairpin turn in it, called a short hairpin RNA (shRNA), to silence the gene that leads to abnormal calcium channel signaling in the striatum that causes dyskinesia. Dr. Steece-Collier also explains how this technique may have advantages over drug therapy to control dyskinesia.
In this episode, Dr. Andrew Cutler interviews Dr. Diana Perkins on best practices for shared decision making and patient education. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD02 Learning Objectives: After completing this educational activity, you should be better able to: Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Diana Perkins, MD, MPH Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC Consultant/Advisor: Alkermes, Karuna Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: May 27, 2022 CE credit expires: May 27, 2025
PT, PTA, OT, OTA – this podcast may help you meet your continuing education requirements. Access Relias Academy to review course certificate information. Have you ever worked with a patient that just doesn't fit the diagnosis? The symptoms, they are not following the expected pattern. In this episode, we talk with Mike Studer about functional neurologic disorder (FND), what it is, common clinical presentation, assessment options, and treatment strategies. (00:30) Introduction (05:25) What Is an FND? (08:50) Common Presentations of FND: Two Case Examples (14:01) Prevalence (14:51) Assessment Options to Confirm Diagnosis (19:25) Case Example Revisited: Whole Body Dyskinesia – Is it FND? (23:18) Triggers (25:41) Using Outcome Measures to Enhance Patient Engagement (28:06) Treatment Strategies for Our Young Athlete (33:30) Educating Referral Providers About FND (36:31) Thorough Work-Up: Recommended or Not? (41:10) Additional Treatment Strategies for Our Older Adult with Dyskinesia (44:28) Load, Remove, and Celebrate: Details are in the Dosage (47:23) Benefits of “Little Wins” (49:15) The Home Exercise Program: Intensity and Functionality (51:23) FND and Chronic Pain (58:46) Summary (1:02:05) Conclusion The content for this course was created by Mike Studer, PT, MHS, NCS, CEEAA, CWT, CSST, FAPTA. The content for this course was created by Tiffany Shubert, PT, PhD. Here is how Relias can help you earn continuing education credits: Access your Relias Library offered by your employer to see course certificate information and exam; or Access the continuing education library for clinicians at Relias Academy Review the course certificate information, and if eligible, you can purchase the course to access the course exam and receive your certificate. Learn more about Relias at www.relias.com. Legal Disclaimer: The content of Stretch: Relias Rehab Therapy Education is provided only for educational and training purposes for healthcare professionals. The educational material provided in this podcast should not be used as medical advice to treat any medical condition in either yourself or others. Resources http://neurosymptoms.org/
In this episode, we review the high-yield topic of Primary Ciliary Dyskinesia from the Pulmonary section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
ONCE UPON A GENE - EPISODE 132 Rare Disease Caregiving Post Childhood with Rare Mom and Advocate Karen McEwen Karen McEwen has an 18 year old daughter with laryngeal cleft primary ciliary dyskinesia (PCD). Her and her daughter have been active advocates through speaking, writing and support groups. They're also fundraising for the PCD Foundation and working to get a PCD clinic at major hospitals in every state. EPISODE HIGHLIGHTS Tell us about your family and your daughter Elana. My daughter Elana is 18 years old and a freshman in college. She has a rare disease called primary ciliary dyskinesia (PCD). I have another daughter, Madison, who is 11 years old and she's healthy. When Elana was born, she coughed before she cried. The doctors said she had fluid in her lungs from birth and that it wasn't anything to worry about. Two days later, she went for a check-up and she was sent for an x-ray. Since then, she's suffered from repeated pneumonia, bronchitis, ear infections, sinus infections and other upper respiratory problems. Elana has had over 60 surgeries, has been hospitalized over 100 times and she's had to get hearing aids as a result of the disease. She's been so resilient through everything. Is it difficult for kids to get diagnosed with PCD? The PCD Foundation has a goal of establishing a PCD clinic in every state. For a PCD diagnosis, the process of collecting samples is very precise and requires special equipment. Having a clinic in each state would provide easier access to diagnostic procedures. Elana and I have spoken at several hospital family day events, medical schools and at rare disease day hoping to spread awareness about PCD and ease the diagnosis journey for affected families. How have things changed with Elana being grown and away at college? I feel like I've been fired. Now that she's 18, she wants to take the lead on her own appointments. After taking her to hundreds of doctors appointments and being through all the hospitalizations, picking her up from school- it was weird to watch her pull out of the driveway and go to an appointment without me. What superpowers do you feel you have? I can learn a lot of new things and do things I never thought possible. Being on this journey with Elana, I've had to learn medical terms, learn how to care for her, research and figure out how to conduct fundraisers, speak at medical conferences and our state capitol. LINKS & RESOURCES MENTIONED PCD Foundation https://pcdfoundation.org/ TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/
Did you know that rocking back and forth isn't a symptom of schizophrenia — it's a side effect of the medication used for treatment. It's called tardive dyskinesia, and it's a common result of long-term use of antipsychotic medications. The percentage of patients who will experience tardive dyskinesia ranges from 3% to as high as 68% and can have a negative impact on quality of life. Dee Linde, who is a support group leader with the Dystonia Medical Research Foundation, joins and shares her incredible journey with tardive dystonia — a progressed form of tardive dyskinesia. Host Rachel Star Withers, a diagnosed schizophrenic, and cohost Gabe Howard discuss the effects of tardive dyskinesia, personal stories, and ways to manage it in this episode of Inside Schizophrenia. To learn more, visit the official episode page here. Guest Bio Dee Linde, MA, is a U.S. navy veteran and worked as a licensed marriage and family therapist for 15 years. Linde was diagnosed with tardive dystonia in 1997 and had deep brain stimulation (DBS) surgery in 2000. In 2002 Linde founded the DBSforDystonia Yahoo group to offer online peer support and information to those on the DBS journey. She now moderates the Dystonia & Deep Brain Stimulation Facebook group. Linde also leads the Portland, Oregon & Southwest Washington Dystonia Support Group. She has served on the Department of Defense's Peer Reviewed Medical Research Program's consumer reviewer panel for dystonia research applications and has testified before the Senate Defense Appropriations Subcommittee urging federal legislators to keep dystonia on the list of conditions included in the Department of Defense's exclusive research program. Linde is a member of the Dystonia Medical Research Foundation's Community Leadership Council, a frequent speaker at DMRF events, and a member of the Dystonia Dialogue newsletter's editorial board. https://dystonia-foundation.org/ Inside Schizophrenia Podcast Host Rachel Star Withers creates videos documenting her schizophrenia, ways to manage and let others like her know they are not alone and can still live an amazing life. She has written Lil Broken Star: Understanding Schizophrenia for Kids and a tool for schizophrenics, To See in the Dark: Hallucination and Delusion Journal. Fun Fact: She has wrestled alligators. To learn more about Rachel, please visit her website, RachelStarLive.com. Inside Schizophrenia Co-Host Gabe Howard is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are also available directly from the author. Gabe makes his home in the suburbs of Columbus, Ohio. He lives with his supportive wife, Kendall, and a Miniature Schnauzer dog that he never wanted, but now can't imagine life without. To learn more about Gabe, please visit his website, gabehoward.com.
Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules. Tim explains, "In the conventional world, which people probably know a lot about, are the orthosteric agonists and antagonists. These molecules are binding to the active site. The way to understand, in simple terms, the difference between an allosteric and an orthosteric drug is to use an analogy of the dimmer light switch." "If you think about the dimmer light switch, you're initially turning the light on-- that would be the orthosteric agonist. Turning the light off would be the orthosteric antagonist, and what Addex is, is the dimmer. We leave the body in charge of turning the light on, so to speak, and then the Addex, allosteric modulator, if it's a positive modulator, we are really turning up the intensity of the light. If it is a negative modulator, we are turning down the intensity, so we're really modulating the intensity of the signal." @AddexPharma #AllostericModulators #CNSDrugDiscovery #NeurologicDrugDiscovery #DrugDevelopment #ParkinsonsDisease #Dyskinesia #Dystonia #Blepharospasm #MovementDisorders Addextherapeutics.com Download the transcript here
Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known as allosteric modulation. This emerging class of small molecule drugs known as allosteric modulators is being explored for treating central nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's and dystonia. Addex did not invent allosteric modulation but is pioneering the screening technologies to find these difficult to locate molecules. Tim explains, "In the conventional world, which people probably know a lot about, are the orthosteric agonists and antagonists. These molecules are binding to the active site. The way to understand, in simple terms, the difference between an allosteric and an orthosteric drug is to use an analogy of the dimmer light switch." "If you think about the dimmer light switch, you're initially turning the light on-- that would be the orthosteric agonist. Turning the light off would be the orthosteric antagonist, and what Addex is, is the dimmer. We leave the body in charge of turning the light on, so to speak, and then the Addex, allosteric modulator, if it's a positive modulator, we are really turning up the intensity of the light. If it is a negative modulator, we are turning down the intensity, so we're really modulating the intensity of the signal." @AddexPharma #AllostericModulators #CNSDrugDiscovery #NeurologicDrugDiscovery #DrugDevelopment #ParkinsonsDisease #Dyskinesia #Dystonia #Blepharospasm #MovementDisorders Addextherapeutics.com Listen to the podcast here
In this episode, Dr. Andrew Cutler interviews Dr. Rajnish Mago on best practices for early detection and screening for tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD01 Learning Objectives: After completing this educational activity, you should be better able to: Conduct regular screenings for symptoms of tardive dyskinesia in patients with mood disorders and schizophrenia Employ evidence-based screening tools in the differential diagnosis of tardive dyskinesia, including the Abnormal Involuntary Movement Scale Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MDClinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Rajnish Mago, MD Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Clinical Assistant Professor, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA Editor-in-Chief, Simple and Practical Medical Education No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: March 23, 2022 CE credit expires: March 23, 2025
Listen to the third chapter, "Motor Symptoms," of the newest edition of our Every Victory Counts® manual. This chapter explains the common motor symptoms of Parkinson's as well as strategies to manage them. Go to https://davisphinneyfoundation.org/podcast-recording-chapter-three-every-victory-counts-manual for related resources and to order your Every Victory Counts manual today. Email blog@dpf.org with any questions, comments, or concerns and to participate in the competition related to this series.
In this latest Episode of Reflections on Parkinson's Disease, Prof's Bloem and Poewe discuss what is meant by ‘on/off' fluctuations and what it entails. They evaluate the ‘good on and the bad on' and consider that when a patient is turned ‘on', medication can sometimes overshoot its target, which means patients develop involuntary movements which are called Dyskinesia's. The Prof's then explore the different types of Dyskenisia's, what problems can arise for patients who are suffering them and also how it can affect their loved ones in everyday life.
© 2020-2025 Ivy Podcast Discovery LLC
